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Abstract   
 
The relationship between circadian phototransduction and circadian-regulated processes 
is poorly understood. Melatonin, commonly a circadian phase marker, may play a direct 
role in a myriad of physiologic processes. The circadian rhythm for pineal melatonin 
secretion is regulated by the hypothalamic suprachiasmatic nucleus (SCN). Its neural 
source of light input is a unique subset of intrinsically photosensitive retinal ganglion 
cells expressing melanopsin, the primary circadian photopigment in rodents and primates. 
Action spectra of melatonin suppression by light have shown that light in the 446–
477 nm range, distinct from the visual system’s peak sensitivity, is optimal for 
stimulating the human circadian system. Breast cancer is the oncological disease entity 
whose relationship to circadian rhythm fluctuations has perhaps been most extensively 
studied. Empirical data has increasingly supported the hypothesis that higher risk of 
breast cancer in industrialized countries is partly due to increased exposure to light at 
night. Studies of tumor biology implicate melatonin as a potential mediator of this effect. 
Yet, causality between lifestyle factors and circadian tumor biology remains elusive and 
likely reflects significant variability with physiologic context. Continued rigorous 
empirical inquiry into the physiology and clinical implications of these habitual, 
integrated aspects of life is highly warranted at this time.  
 
Introduction 
The relationship between circadian phototransduction, endogenous melatonin levels, 
endocrine hormone physiology, and the myriad of normal and pathological circadian-
regulated processes is far from being fully illuminated1,2. Many mutually consistent 
associations have been made between the light exposure history of an organism, circadian 
clock gene regulation, melatonin secretion, and the dysregulation of cell biology in 
cancer1,3, but the specifics of these relationships are still poorly understood. It is well 
established that light of sufficient intensity has an acute suppressive effect upon the 
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secretion of melatonin from the human pineal gland and that this suppression directly 
reflects the action of a non-visual photoreceptive system in circadian phototransduction4. 
The health implications of this suppressive potential of light upon melatonin, however, 
have only recently begun to be addressed.  
Melatonin has been used frequently as a scientific marker of circadian phase5, or a 
biochemical marker of darkness6. Nevertheless, there is accumulating evidence that 
melatonin, as related to sleep/wake cycles and circadian physiology in general, may have 
a more direct role in several physiologic processes, spanning the fields of psychiatry, 
psychoneuroimmunology, oncology, and reproductive endocrinology7. For example, 
melatonin and circadian disturbance have been implicated in the pathophysiology of 
Seasonal Affective Disorder (SAD)7-10, and light therapy has been shown to be an 
effective treatment for this syndrome11-13. Low serum melatonin concentrations and 
urinary metabolite levels have also been found in women with estrogen-receptor positive 
breast cancer and men with prostate cancer14-16. More specifically, melatonin has been 
shown to have antiproliferative effects on neoplasms of several tissue types in vitro and 
in vivo 17,18, to possess related antioxidant effects 7, 19-21, and to have immunostimulatory 
effects7,22.  
Relatedly, some evidence suggests that alterations to endogenous reproductive hormone 
physiology, particularly the menstrual cycle length, may be a common pathway through 
which disruptions to melatonin and circadian rhythms affect breast cancer development 
and progression23. Animal studies have demonstrated that melatonin can, via influence 
upon gonadotropin-releasing hormone (GnRH) release in the hypothalamic–pituitary 
axis, affect gonadotropin (LH and FSH) release from the pituitary gland and, in turn, 
gonadal function. There is some indirect evidence in humans consistent with these 
findings, though the implications are still quite unclear21,24. For example, a correlation 
has been made between the stage of breast cancer and inversely proportional changes in 
nocturnal melatonin levels in breast cancer patients15. One study showed that the addition 
of melatonin to the traditional pharmacologic management of metastatic breast cancer 
appeared to slow disease progression21,25. Consistent findings have been shown in other 
cancer types21,26-27. Additionally, the oncostatic action of melatonin on human breast 
cancer has been linked to estrogen response21,28, with interactions occurring between 
melatonin and estradiol to influence breast cancer cell development21,29. This relationship 
between the hormones does not appear to be reciprocal, however, as it has been shown 
that the menstrual cycle phase and reproductive hormone status does not affect a 
woman’s melatonin secretion7 or sensitivity to melatonin suppression by light30.  
The complexity and importance of the interactions between light, the circadian system, 
and subsequent disturbances in hormone physiology and cancer is highlighted by the 
body of scientific evidence surrounding the relationship between light and breast cancer. 
Tissue-specific circadian clock organization in both normal and neoplastic proliferative 
tissue has the potential to accelerate tumor growth31. Similarly, the direction of melatonin 
rhythm entrainment to light stimuli as an advance or delay of the nighttime peak, is 
dependent upon the circadian time of the endogenous rhythm upon which the stimulus is 
superimposed32. This plasticity of response, however, like every other dynamic 
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physiologic process that occurs within the context of changing internal and external 
biological environments, is likely compounded by unique variations in response at 
different points along the pathways of light transmission. The concept of tissue-specific 
circadian programming via varied expression of clock genes is one mechanism of this 
plasticity, for example1. Regardless, any effort to begin clarifying this complexity is 
dependent upon an understanding of the incipient alterations that occur in the biological 
response to light, specifically, in circadian phototransduction.  
The first dominos in the biological effect of light 
 
The circadian rhythm for melatonin secretion is regulated by the endogenously generated 
rhythm of the hypothalamic suprachiasmatic nuclei (SCN), via an indirect multi-synaptic 
pathway to the pineal gland. This intrinsic rhythm is, in turn, synchronized by light input 
from the environment to the SCN via the direct projections of the retinohypothalamic 
tract (RHT)33. A simplified diagram of the elements of this circuitry is shown in Figure 1. 
The source of these projections to the SCN is a unique subset of intrinsically 
photosensitive retinal ganglion cells (ipRGCs)34-37, and these intrinsically photosensitive 
ganglion cells have been shown to be in the same subset of retinal cells that express 
melanopsin38-39.  
Initially, the search for an alternate circadian photoreceptor included both opsin-based 
molecules such as RPE-retinal G protein-coupled receptor, peropsin, encephalopsin, and 
melanopsin as well as non-opsin molecules like cryptochrome40. Cryptochrome was an 
early candidate as a nonvisual photoreceptor in mammals since it plays a central role in 
circadian photoreception in lower species41. Current evidence, however, suggests that the 
two cryptochrome homologs found in the inner retina of mammals are not strictly 
required for mammalian circadian phototransduction, but may have an accessory function 
in inner retinal phototransduction42.  
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Fig. 1 Light influences melatonin secretion from the pineal gland via a multi-synaptic, indirect 
neural circuit. Light enters the eye through the pupillary aperture, stimulates the retina and sends 
its signal to the circadian pacemaker, the SCN, via a direct retinohypothalamic projection (RHT). 
Not shown here is the accessory connection between an integrating center in the thalamus, the 
intergeniculate leaflet (IGL), and the SCN. The IGL provides a second neural pathway for light to 
influence the circadian pacemaker. From the SCN, impulses travel to the pineal gland by first 
synapsing at the paraventricular nucleus of the hypothalamus, descending to synapse in the 
interomediolateral cell column (IMLCC) of the upper thoracic spinal cord, projecting to the 
superior cervical ganglion, and finally ascending along the cerebral vasculature to its final synapse 
at the pineal gland33 
 
 
Recent evidence has confirmed that melanopsin is a primary photopigment mediating 
circadian phototransduction in rodents and primates43-46. Specifically, cells which are 
inherently incapable of photoreception were rendered photoreceptive after heterologous 
expression of human melanopsin43-46. It has been shown that the ipRGCs in rats and 
monkeys will depolarize in response to light with a peak spectral sensitivity around 
480 nm, even with the blockage of synaptic input from rods and cones34. Furthermore, 
studies in rodents with retinal degeneration have indicated that neither the rod nor cone 
photoreceptors necessarily participate in circadian responses to light, including melatonin 
suppression and photoperiodic response47-49. Thus, both the anatomical distribution and 
physiologic profile of melanopsin indicate that this photoreceptive system is a 
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fundamental gateway for influencing the SCN’s perception of light stimuli in the 
environment, and consequently, the responses of many dependent biological processes.  
The acute suppression of plasma melatonin by light is a well-defined means of measuring 
the sensitivity of this non-visual photoreceptive system4,50, regardless of any downstream 
effects of the synthesized melatonin. Action spectra of melatonin suppression by light in 
healthy human subjects have shown that light in the 446–477 nm range is optimal for 
stimulating the circadian system and eliciting this suppression response51-52. This peak is 
distinct from the peak sensitivity of the three-cone photopic visual system, as well as 
each of the individual rods and cones for vision51-53. A study demonstrating that 460 nm 
monochromatic light is significantly more potent than 555 nm for phase-shifting the 
circadian pacemaker of healthy humans offers specific evidence to show that the peak 
sensitivity of the human circadian pacemaker is distinct from that of the classical three-
cone system for photopic vision54. Figure 2 illustrates the two distinct photosensitivity 
inputs for vision and melatonin suppression.  
 
 
 
Fig. 2  Comparison of action spectra for the novel, melanopsin-based circadian photoreceptive 
system and the photopic, classical cone photoreceptors. The circadian action spectrum peaks in the 
446–477 nm range, versus a 555 nm peak for the three cone visual system  
Of note, however, it is apparent that the rods and cones, though not essential to the 
circadian response to light stimuli, appear to have a role in circadian photoreception 
under normal physiologic conditions. For example, retinally degenerate mice, while still 
maintaining the capacity for circadian photoreception and response to light, have a 
spectral sensitivity for circadian phase-shifting that is different from wild-type mice with 
normal functioning rods and cones55. There is also a residual phase shifting response in 
melanopsin genetic knock-out mice which suggests an alternate or redundant means for 
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light input to the SCN56. Studies in transgenic rodent models suggest that rod and cone 
photoreceptors have the capacity to transduce light for circadian regulation57. The extent 
to which these basic molecular findings in other mammals can be carried over in 
application to humans is still unknown, however the evidence to date in humans and non-
human primates suggests there is a high level of correlation39,46. For example, it has been 
shown in humans that there is a bidirectional, mutual input potential between the novel, 
non-classical opsin-based photopigment and the classical rod-cone photoreceptors, 
where, under normal conditions, the novel circadian photopigment has a measurable role 
in rod and cone adaptation to light over time58. The SCN, itself, is also capable of 
receiving integrated neural information from the intergeniculate leaflet (IGL) of the 
thalamus, which itself receives retinal projections from the rod and cone visual system59. 
Thus, light has at least two neural pathways for stimulating the SCN in the process of 
entrainment, phase-shifting, or melatonin suppression. The light-induced regulation of 
melatonin or the broader circadian system can, in turn, potentially alter other physiologic 
processes downstream to a degree of magnitude which is still unknown.  
The distinction between visual and circadian photoreception has been demonstrated on an 
empiric level as well. Blind persons who have no residual perception of light stimuli have 
nonetheless shown a melatonin suppression and circadian phase-shifting responses to 
bright light exposure60-61. Similarly, colorblind individuals appear to maintain this light-
induced melatonin suppression62. The epidemiologic evidence showing a significantly 
decreased risk of breast cancer in women with profound bilateral blindness as compared 
with normally sighted women63-64 suggests a correlation between these findings and the 
oncostatic properties of melatonin in the setting of cancer. Also supporting the idea of 
circadian melatonin regulation via a non-visual photoreceptive system as an endocrine 
link between light and reproductive hormone disturbances is the finding that blindness in 
human females is associated with an age of menarche that is earlier than normal and 
proportional to the level of light perception loss65.  
Finally, although less sensitive than the visual system, circadian photoreception appears 
to be capable of responding to relatively low levels of light4,5,66-68. It has been shown in 
laboratory animals that indirect light as dim as 0.2 lux (0.06 μW/cm2) has the capacity to 
significantly suppress nocturnal plasma melatonin levels and consequently increase 
hepatoma growth69-70. At the same time, however, circadian photoreception appears to 
involve a still poorly characterized and complicated method of integration of light stimuli 
over time by the photoreceptors themselves58, further downstream at the SCN71, and even 
more broadly on a tissue-specific level1. More recently, specific molecular findings are 
highly suggestive of melanopsin behaving more like an invertebrate opsin in nature than 
a vertebrate opsin and acting more like a photopigment than a photoisomerase 
influencing some other still-unknown opsin molecule58. The implications of these 
findings are far-reaching with regard to questions of photoreceptor adaptation and 
bleaching, for recent light history does appear to attenuate the response of subsequent 
melatonin suppression by bright white light72-73. Yet this varied circadian photoreceptive 
response throughout time cannot be accounted for by simple photon summation over the 
period of observation54. Summarily, it appears that circadian photoreception has specific 
spectral parameters for optimal response and a very low threshold for excitation, but 
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these characteristics cannot be accurately considered in isolation from their 
environmental, biological, and behavioral context.  
Circadian light measurement 
With such a distinct photoresponse profile, it has become increasingly apparent that 
traditional means of light measurement do not suffice to provide an accurate point-in-
time measurement of light input to the mammalian circadian system. For more than 
25 years, research surrounding human circadian physiology has primarily used a 
photometric-based description and light measurement system5,74. The use of this 
measurement perspective, however, implies that the human visual (rod and cone 
photoreceptor) system is the primary system involved in circadian photoreception. A 
series of recent human experiments employing standard photobiological techniques have 
shown, specifically, that lux measurements are inappropriate for circadian, 
neuroendocrine, and therapeutic purposes. Specifically, equal photon doses of short-
wavelength monochromatic light evoke a stronger acute melatonin suppression 
responses, circadian phase-shifts, core body temperature changes, subjective sleepiness, 
heart rate, auditory reaction time, and auditory lapses in human subjects, when compared 
with longer wavelength light at the peak of the photopic sensitivity curve51-54,75. The 
importance of this distinction in light measurement is demonstrated by the finding that, 
under optimum exposure conditions, as little as 5 lux of 460 nm light evokes an 
equivalent phase shift (3 h phase delay) when compared with 10,000 lux white 
fluorescent light54.  
Thus, the characterization of light exposures for non-visual photobiological responses, 
including melatonin suppression, circadian phase-shifting, and tumor growth, should 
include radiometric quantification of irradiance and spectral power distribution76-77.  
Furthermore, the implication of these findings for understanding the influence of various 
lighting conditions upon subsequent tumor development in vivo is to highlight the need 
for increased research conducted under conditions that emulate the daily photic 
environment of humans.  
The time of light 
 
The circadian system’s sensitivity to light stimuli varies immensely with both the 
circadian phase and the end effect being measured. It has been shown that practically all 
normal proliferating tissues have been shown to undergo circadian variation in DNA 
synthesis and mitotic index across a 24 h period, and similar variations appear to exist in 
tumor tissues depending upon the type and stage of growth31,78. Furthermore, as indicated 
in Figure 3, this tissue-specific rhythm is not necessarily directly reflective of broader, 
overarching circadian rhythms regulated by the biological master clock in the SCN1. 
Many anticancer agents have limiting cytotoxic effects on normal tissues that vary with 
cell proliferative activity and cell cycle stage78. Thus, an understanding of the 
characteristics of this circadian variation in response to a given light stimulus is highly 
germane to clarifying the relationship between light and cancer. Gaining utility of this 
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differential response of normal and neoplastic tissues to chemotherapy according to 
circadian state has the potential to maximize chemotherapeutic efficacy while minimizing 
toxicity. Advantages for circadian scheduling of chemotherapies have in fact already 
been shown to diminish side effects and increase the maximum tolerated doses for 
increased tumor response78.  
 
 
 
Fig. 3 Cell growth and division follows a tissue-specific program that is influenced by, but not 
homologous with, the SCN master clock rhythm. Solid arrows represent primary neural influence. 
Dotted arrows represent secondary synaptic influence. Figure adapted from Hastings, et al.1  
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Light exposure during darkness and breast cancer 
Breast cancer is the oncological disease entity whose relationship to circadian rhythm 
fluctuations has been brought most extensively to the attention of both clinical and basic 
science research. It has been shown that otherwise healthy women who are chronically 
subjected to nighttime shiftwork, and thus to light exposure at night, have a higher 
incidence of breast cancer79-80. Epidemiologically, the World Health Organization 
estimated in 1980 that half of all cancer in the world occurred in areas comprising one-
fifth of the world’s population, namely industrialized countries81. Thus, it has been 
hypothesized that the increased risk of breast cancer in industrialized countries is due, in 
part, to increased exposure to light at night, relative to unindustrialized countries who 
have significantly fewer nightshift workers23,82-83.  
Increasingly, published empirical data has been supporting this hypothesis. Melatonin has 
been shown, at physiologic concentrations, to have a direct inhibitory effect on human 
breast cancer cells in vitro21 and even more recently, in vivo18,84. It has also been 
established that light of sufficient intensity at night has the capacity to acutely inhibit the 
normal nocturnal rise in melatonin in humans4,21,85. This, in turn, would suggest that any 
environmental exposure which results in a relative decrease in integrated melatonin levels 
over time would consequently result in less oncostatic protection and a higher rate of 
breast cancer development and/or proliferation. This theoretical construct is consistent 
with epidemiologic findings80, as well as the melatonin-breast cancer hypothesis82. With 
acute light-induced melatonin suppression, however, there is likely to be coincident 
disruption of circadian phase and/or entrainment. Thus, it has not yet been determined if 
light exposure at night is a risk specifically due to acute melatonin suppression, to 
circadian disruption, or both.  
The majority of studies have demonstrated a marked stimulatory effect of either 
pinealectomy or constant light exposure on tumor development and growth21,86. In 
general, following pinealectomy or exposure to constant bright light, not only do tumors 
appear earlier, but a greater percentage of animals develop tumors and more tumors 
develop per animal as compared to control animals maintained on an alternating 12 h 
light:12 h dark cycle. Although constant light exposure seems to stimulate tumorigenesis 
in the majority of investigations, clearly one-third of the studies conducted report either 
inhibitory, mixed or no effects on the development of experimental cancer. Interestingly, 
more consistent stimulatory actions of continuous illumination appear to occur with 
respect to the growth of established tumors86. In rats bearing either tissue-isolated rat 
liver cancer (i.e., hepatoma) or rat mammary cancer, constant bright light exposure (i.e., 
300 lux at eye level) for one week prior to tumor implantation and continuing thereafter, 
completely suppresses the nocturnal, circadian rise in circulating melatonin levels, as 
compared with L:D controls. Tumors appear much earlier as a result of constant light 
exposure and their average daily growth rate accelerates by a factor of 2.5–6 times over 
the average growth rate of tumors in the L:D control group. The marked increase in the 
rates of tumor growth results from a substantial augmentation in the rate of rumor uptake 
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of linoleic acid (LA) and its conversion to 13-hydroxyoctadecadienoic acid (13-HODE) 
as a consequence of the suppression of the circadian melatonin signal69-70,87.  
The ability of ocular light exposure to suppress pineal melatonin production depends on 
the intensity, wavelength, duration, and timing of light. As important as the constant 
bright light studies are, they address only one aspect of the intensity issue. Previous 
studies have demonstrated that the exposure of rats to low intensity fluorescent light (i.e., 
0.2 lux at rodent eye level) during the dark phase for one week prior to the implantation 
of tissue-isolated rat hepatomas, results in a nearly complete suppression of circulating 
melatonin levels. Interestingly, the tumor growth rate, LA uptake, and metabolism to 13-
HODE are nearly as rapid as in constant light-exposed animals, indicating that low 
intensity light-induced melatonin suppression during the dark phase is as effective as 
constant light exposure in tumor growth and LA metabolism69-70. Even more recent 
studies have examined the effects of different light intensities during darkness on 
nocturnal circulating melatonin levels and the growth and LA metabolism of rat 
hepatoma 7288CTC88. Exposure of tumor-bearing rats to fluorescent light intensities (at 
rodent eye level) ranging from complete darkness to constant bright light (345 μW/cm2 or 
∼840 lux) results in a dose-dependent suppression of melatonin levels with a concomitant 
dose-related stimulation of tumor growth, LA uptake and 13-HODE production88. These 
findings represent the first evidence that stimulation of tumor growth and metabolism is 
dependent on the degree of the suppression of melatonin production that is, in turn, 
dependent upon the intensity of light present during darkness. Studies are currently 
examining fluence–response issues relative to melatonin suppression and the growth and 
LA metabolism of human breast cancer xenografts in nude rats. Furthermore, other 
ongoing studies are focusing on the role of the nocturnal, circadian melatonin signal, and 
its suppression by light during darkness in human volunteers, on human breast cancer 
xenograft growth and LA metabolism.  
The light-melatonin-breast cancer hypothesis, with specific regard to human breast 
carcinogenesis, has not been directly addressed until recently. This has been done using a 
strain of athymic female rats in which human breast cancer xenografts grow quite well. 
During a two week period following their transfer from a 12L:12D light:dark cycle (i.e., 
intact circadian melatonin signal) to constant 300 lux bright light (i.e., no nocturnal 
melatonin signal), the average daily rate of tumor growth in constant light-exposed rats 
increased by seven-fold in comparison to the tumor growth rate in animals remaining on 
an L:D cycle. This accelerated rate of human breast cancer growth was initiated and 
sustained as a result of increases in the rate of tumor uptake of LA and its metabolism to 
13-HODE. This augmented rate of tumor LA uptake and metabolism resulted from 
constant light-induced suppression of the circadian melatonin signal which normally 
drives the inhibition of these processes during the dark phase84. This is the first 
experimental evidence to date showing a link between inappropriate exposure to 
continuous bright light and increased growth and fatty acid metabolism of human breast 
cancer.  
Thus, a better understanding of the photobiology underlying the effects of light upon 
endogenous melatonin rhythm offers potential to further scientific understanding of the 
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development and maintenance of oncologic processes. More specifically, the response of 
this dynamic system to changes in light intensity, spectral quality, and varied light 
exposure history is highly germane to gaining a better understanding of the potential 
relationships between light exposure and cancer risk. Elucidating the underlying photic 
input physiology to the pineal gland and subsequent melatonin regulation may provide a 
common doorway to influence both normal neuroendocrine homeostasis as well as 
oncological processes. Ultimately, rationally integrated lifestyle approaches may one day 
be used to prevent the development of some breast cancers as well as to restore health in 
some cancer patients.  
Conclusion 
Concomitant molecular and empiric investigations of the relationship between light and 
cancer have begun to scratch the surface of this clinically expansive area of research. 
Still, clinical applications and shifts in theoretical structure are slow to follow scientific 
developments, and there is much room for future investigations to begin clarifying these 
ideas and give form to this promising evidence. For example, from a purely clinical 
perspective, etiologic theorizing concerning human breast cancer has centered primarily 
upon estrogen, its receptors, and the genetic inheritance of traits that influence their 
relationship. Currently, a patient’s integrated estrogen exposure over time is perhaps one 
of the most exigently debated breast cancer risk factors. Accordingly, the personal 
historical elements which are most commonly analyzed in the primary survey of a 
patient’s risk and/or prognosis for breast cancer include: age at onset of menarche and 
menopause, age of first term pregnancy and number of pregnancies, as well as personal 
and family history of pre-menopausal breast cancer 89-91. In contrast, the patient’s 
sleep/wake cycle, melatonin rhythm, light history, and work schedule are not typically 
considered as being relevant to this cancer risk assessment, in spite of the growing body 
of evidence supporting this possibility.  
While accumulating evidence points toward potential for the various work schedule and 
lifestyle factors to influence tumorigenesis and progression, causality remains elusive and 
likely reflects significant variability with physiologic context. For example, it seems that 
the pathway by which melatonin influences tumor development and progression is 
dependent upon fatty acid availability and metabolism18,70. High fat consumption has not 
been consistently correlated with an increased risk of breast cancer in humans92, but 
increased constitutional fat content in obese females is correlated with higher levels of 
endogenous estrogen, which may, in turn, be the effector that potentiates many 
gynecologic neoplasms, such as breast cancer93. Furthermore, dietary constituents have 
been correlated with increased risk of other cancers, but the molecular players within this 
risk are yet to be consistently identified92,94.  
Light exposure, the status of physiologic circadian rhythms, diet95, and exercise habits95, 
though recognized as bearing a potential influence on cancer outcome, are less well-
defined in their roles in cancer pathophysiology and are consequently often given 
subordinate attention in clinical approaches to cancer96. Continued rigorous empirical 
inquiry into the physiology and clinical implications of these habitual, integrated aspects 
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of life is highly warranted at this time. Ultimately, when the weight of evidence becomes 
compelling, the traditions of clinical practice will be adjusted to reflect the relationship 
between light and cancer that current evidence suggests.  
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